Syndax Pharmaceuticals (SNDX) Other Non Operating Income (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Other Non Operating Income of -$186000.0 for Q1 2026, up 15.84% year-over-year from -$160570.3 in Q1 2025, and up 68.26% quarter-over-quarter from -$586000.0 in Q4 2025.
Powered by 
Analysis
Syndax Pharmaceuticals (SNDX) Other Non Operating Income (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Other Non Operating Income history runs 12 years deep, the most recent figure standing at -$186000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 15.84% year-over-year to -$186000.0; the TTM figure through Mar 2026 stood at -$1.3 million (down 232.81% YoY), while the FY2025 annual figure was -$1.3 million, down 419.43% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$186000.0, up from -$586000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $116000.0 in Q1 2022, with the low at -$586000.0 in Q4 2025.
- The 5-year median for Other Non Operating Income is -$99500.0 (2022), against an average of -$137000.0.
- The sharpest annual moves came in 2022 and 2025: Other Non Operating Income surged 303.51% in 2022, then sank 959.38% in 2025.
- Syndax Pharmaceuticals' Other Non Operating Income stood at -$106000.0 in 2022, then surged by 48.11% to -$55000.0 in 2023, then plunged by 92.73% to -$106000.0 in 2024, then tumbled by 452.83% to -$586000.0 in 2025, then soared by 68.26% to -$186000.0 in 2026.
- Business Quant data shows SNDX's Other Non Operating Income at -$186000.0 in Q1 2026, -$586000.0 in Q4 2025, and -$275000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Syndax Pharmaceuticals | 1.83 Bn | 1.28 Bn | 60.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -438,000.00 |
| Mar 31, 2026 | -186,000.00 |
| Dec 31, 2025 | -201,000.00 |
| Sep 30, 2025 | -275,000.00 |
| Jun 30, 2025 | -586,000.00 |
| Mar 31, 2025 | -221,000.00 |
| Dec 31, 2024 | -106,000.00 |
| Sep 30, 2024 | 32,000.00 |
| Jun 30, 2024 | -86,000.00 |
| Mar 31, 2024 | -87,000.00 |
| Dec 31, 2023 | -55,000.00 |
| Sep 30, 2023 | -66,000.00 |
| Jun 30, 2023 | -93,000.00 |
| Mar 31, 2023 | -147,000.00 |
| Dec 31, 2022 | -106,000.00 |
| Sep 30, 2022 | -295,000.00 |
| Jun 30, 2022 | -31,000.00 |
| Mar 31, 2022 | 116,000.00 |
| Dec 31, 2021 | 351,000.00 |
| Sep 30, 2021 | -41,000.00 |